Clinical trials: Alcoholic Liver Disease
NAFLD (Nonalcoholic Fatty Liver Disease)
A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.
The goal of this clinical trial is to learn if drugs Dapagliflozin and Empagliflozin work to treat NAFLD in Type 2 diabetes patients. It will also learn about the safety of drugs dapagliflozin and empagliflozin.
- Trial name
- (Dapa)& (Empa) (NCT07363707)
- Testing
- Dapagliflozin + Metformin, Empa
- Where
- Egypt
- Volunteers
- 108 people
- Sponsor
- Beni-Suef University
Non-Alcoholic Fatty Liver Disease
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study
Over the past 30 years, the prevalence of childhood obesity in the United States has tripled from 5% to 15%. Major consequences of obesity include insulin resistance, type- 2 diabetes, cardiovascular disease and nonalcoholic…
- Trial name
- NCT01285362
- Testing
- Fish Oil Supplementation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Columbia University
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Non-alcoholic Fatty Liver Disease (NAFLD)
Elucidating Hepatic Metabolism in Non-alcoholic Fatty Liver Disease
The goal of this observational, cross-sectional, case-control clinical study is to investigate the metabolic adaptations underlying the progression of nonalcoholic fatty liver disease (NAFLD), and to test the hypothesis that…
- Trial name
- ECHO (NCT06942312)
- Testing
- Ketoisocaproic acid breath test, Ammonium Chloride, Bicarbonate de sodium
- Where
- Finland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Non-alcoholic Fatty Liver Disease
SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD
The clinicopathological analyses revealed that reduction in HbA1c and use of insulin independently contribute to the reduction in liver fibrosis scores during the histological course of NAFLD development.
- Trial name
- NCT02649465
- Testing
- Tofogliflozin, Glimepiride
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Kanazawa University
Iron, Diabetes
Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease
This is a treatment study to determine if reducing the body's iron stores by blood donation will improve diabetes control and other problems associated with diabetes such as fatty liver disease.
- Conditions
- Iron, Diabetes, Nonalcoholic Fatty Liver
- Trial name
- NCT03696797
- Testing
- Blood Donation
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- Wake Forest University Health Sciences
Non-alcoholic Fatty Liver
High-intensity Interval Training Versus Moderate Intensity Continuous Training on Gut Microbiota in Non-alcoholic Fatty Liver
To compare High-Intensity Interval Training versus moderate intensity continuous training on gut microbiota in Non- Alcoholic Fatty Liver.
- Trial name
- NCT07697313
- Testing
- High intensity interval training, moderate intensity continuous training, Mediterranean diet
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Horus University
Non-alcoholic Steatohepatitis, Type 2 Diabetes Mellitus
Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease
Primary Objective: To evaluate the dose response relationship of SAR425899 compared to placebo on resolution of non-alcoholic steatohepatitis (NASH) with no worsening of fibrosis in diabetic and non-diabetic patients with…
- Trial name
- Restore (NCT03437720)
- Testing
- SAR425899
- Sponsor
- Sanofi
Fatty Liver, Nonalcoholic
Probiotic Supplement Versus Placebo for the Treatment of Patients With Non-alcoholic Fatty Liver Disease
Probiotic supplement versus placebo for the treatment of patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial
- Trial name
- NCT06491342
- Testing
- Probiotic
- Where
- 2 sites in Thailand
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Phramongkutklao College of Medicine and Hospital
Non-alcoholic Steatohepatitis NASH
Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH
The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH
- Trial name
- NCT02913105
- Testing
- LMB763
- Where
- 30 sites in United States, Australia and 6 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus
Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI
The aim of the prospective observational DISTEMI-Study in people with and without Diabetes mellitus (DI) after new onset of ST-Segment Elevation Myocardial Infarction (STEMI) aged 18-80 years at inclusion into the study is to…
- Conditions
- ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus, Insulin Resistance, Non-Alcoholic Fatty Liver Disease
- Trial name
- DISTEMI (NCT05046483)
- Where
- Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- German Diabetes Center
Diabetes Mellitus, Type 2, Overweight and Obesity
Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes. The Hypo-energetic Study
Scientific evidence for the dietary treatment of type 2 diabetes (T2D) is insufficient, which is why the investigators aim to reform dietary recommendation to the overweight or obese patient with type 2 diabetes.
- Trial name
- CutDM-Hypo (NCT03814694)
- Testing
- CRHP Diet, CD Diet
- Where
- Denmark
- Volunteers
- 72 people
- Sponsor
- Bispebjerg Hospital
Severe Alcoholic Hepatitis
Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis- Assessment of Impact on Prognosis and Short-term Outcome
Alcoholic liver disease has become one of the foremost causes of chronic liver disease across the world, and a cause of considerable morbidity and mortality.
- Trial name
- NCT03827772
- Testing
- Fecal Microbiota Transplantation, Standard of care treatment
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Liver Steatoses
Subclinical Cardiovascular Changes in NAFLD Patient (Predictive Value of Speckle Tracking Echocardiography )
the goal of this study (observational study ) is to learn about the subclinical cardiovascular changes in patients with nonalcoholic fatty liver . the main questions it aims to answer are 1.
- Trial name
- NCT05790057
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Non-Alcoholic Fatty Liver Disease
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAR 502 in Healthy Subjects
This is a prospective, single-center, randomized, double-blind, placebo-controlled, single-ascending dose (SAD) phase 1 study to evaluate the safety and tolerability of single-ascending doses of BAR 502 in healthy male and female…
- Trial name
- NCT05203367
- Testing
- BAR502
- Where
- Portugal
- Volunteers
- healthy volunteers welcome
- Sponsor
- BAR Pharmaceuticals s.r.l.
Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH)
Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant
The primary objective of this study is to evaluate the pharmacokinetics (PK) of miricorilant in the presence and absence of the strong cytochrome P450 [(CYP) 2C19] inhibitor, fluvoxamine, in healthy participants.
- Trial name
- NCT05712265
- Testing
- Miricorilant, Fluvoxamine
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Metabolic Dysfunction-Associated Steatotic Liver Disease
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease…
- Trial name
- NCT07165028
- Testing
- Tirzepatide, Retatrutide
- Where
- 563 sites in United States, Argentina and 32 more
- Volunteers
- 4,500 people
- Sponsor
- Eli Lilly and Company
Sleep Apnea, Obstructive, Hepatocellular Carcinoma
Sleep Apnoea Syndrome and Hepatocellular Carcinoma
Obstructive sleep apnea (OSA), one of the most frequent respiratory diseases, could represent a major worsening factor in a non alcoholic steatohepatitis and neoplastic context.
- Conditions
- Sleep Apnea, Obstructive, Hepatocellular Carcinoma, Non Alcoholic Steato Hepatitis
- Trial name
- ECHAPS (NCT04190498)
- Testing
- Nocturnal oximetry
- Where
- France
- Sponsor
- University Hospital, Grenoble
NASH - Nonalcoholic Steatohepatitis
A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)
A Phase 2, Double-Blind (DB), Randomized, Placebo-Controlled Study Followed by an Open-Label Extension Period to Evaluate the Activity of Seladelpar in Subjects with Nonalcoholic Steatohepatitis (NASH) OLE phase was not analyzed…
- Trial name
- NCT03551522
- Testing
- Seladelpar
- Where
- 14 sites in United States
- Volunteers
- 181 people
- Sponsor
- Gilead Sciences
Non-Alcoholic Fatty Liver Disease, Obesity
Optimal Exercise Frequency to Reduce Liver Fat in Centrally Obese Adults With Non-Alcoholic Fatty Liver Disease
This study aims to examine the comparative effectiveness of different exercise frequencies (once-a-week vs. thrice-a-week) for reducing liver fat in centrally obese adults with non-alcoholic fatty liver disease (NAFLD), with…
- Trial name
- NCT05741957
- Testing
- Once-a-week Exercise, Thrice-a-week Exercise, Usual Care Control
- Where
- Hong Kong
- Volunteers
- 300 people
- Sponsor
- The University of Hong Kong
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.